Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

August 31, 2027

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

Odetiglucan

Odetiglucan 4 mg/kg IV every 3 weeks

DRUG

Mitazalimab

Mitazalimab 0.9 mg/kg IV every 3 weeks

All Listed Sponsors
collaborator

Lustgarten Foundation

OTHER

lead

University of Pennsylvania

OTHER

NCT07199764 - Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter